Survivin is a potential mediator of prostate cancer metastasis

Min Zhang, John J. Coen, Yoshiyuki Suzuki, Michael R. Siedow, Andrzej Niemierko, Li Yan Khor, Alan Pollack, Yifen Zhang, Anthony L. Zietman, William U. Shipley, Arnab Chakravarti

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose: We examined whether Survivin expression is associated with an increased risk of metastasis in prostate cancer. Methods and Materials: A total of 205 patients with T1 (23%) and T2 (77%) prostate cancer were treated with conventional external beam radiation therapy from 1991 to 1993 at the Massachusetts General Hospital. Of the patients, 62 had adequate and suitable-stained tumor material for Survivin analysis. Median follow-up was 102 months (range, 5-127 months). Distant failure was determined on the basis of clinical criteria. In preclinical studies, replication-deficient adenovirus encoding phosphorylation-defective Survivin Thr34→Ala dominant-negative mutant pAd-S(T34A) or short hairpin RNA (shRNA) was used to inhibit Survivin in prostate cancer models, and the cell motility, morphology, and metastasis were investigated. Results: Our correlative data on men with early-stage (T1/T2) prostate cancers treated at Massachusetts General Hospital by definitive radiotherapy indicated that overexpression of Survivin (positive staining in ≥10% cells) was associated with a significantly increased risk for the subsequent development of distant metastasis (p = 0.016) in the univariate analysis. In the multivariate analysis, overexpression of Survivin remained an independent predictor of distant metastasis (p = 0.008). The inhibition of Survivin dramatically inhibited invasiveness of prostate cancer cells in the in vitro invasion assay and spontaneous metastasis in the Dunning prostate cancer in vivo model. Furthermore, attenuation of Survivin resulted in changes in the microtubule cytoskeleton, loss of cellular polarity, and loss of motility. Conclusions: This study suggests that Survivin may be a potentially important prognostic marker and promising therapeutic target in metastatic prostate cancer.

Original languageEnglish
Pages (from-to)1095-1103
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume78
Issue number4
DOIs
StatePublished - Nov 4 2010

Fingerprint

metastasis
Prostatic Neoplasms
cancer
Neoplasm Metastasis
locomotion
General Hospitals
radiation therapy
Radiotherapy
adenoviruses
phosphorylation
staining
Cytoskeleton
cells
Adenoviridae
Microtubules
markers
Small Interfering RNA
Cell Movement
polarity
coding

Keywords

  • Metastasis
  • Prostate cancer
  • Survivin

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Zhang, M., Coen, J. J., Suzuki, Y., Siedow, M. R., Niemierko, A., Khor, L. Y., ... Chakravarti, A. (2010). Survivin is a potential mediator of prostate cancer metastasis. International Journal of Radiation Oncology Biology Physics, 78(4), 1095-1103. https://doi.org/10.1016/j.ijrobp.2009.09.007

Survivin is a potential mediator of prostate cancer metastasis. / Zhang, Min; Coen, John J.; Suzuki, Yoshiyuki; Siedow, Michael R.; Niemierko, Andrzej; Khor, Li Yan; Pollack, Alan; Zhang, Yifen; Zietman, Anthony L.; Shipley, William U.; Chakravarti, Arnab.

In: International Journal of Radiation Oncology Biology Physics, Vol. 78, No. 4, 04.11.2010, p. 1095-1103.

Research output: Contribution to journalArticle

Zhang, M, Coen, JJ, Suzuki, Y, Siedow, MR, Niemierko, A, Khor, LY, Pollack, A, Zhang, Y, Zietman, AL, Shipley, WU & Chakravarti, A 2010, 'Survivin is a potential mediator of prostate cancer metastasis', International Journal of Radiation Oncology Biology Physics, vol. 78, no. 4, pp. 1095-1103. https://doi.org/10.1016/j.ijrobp.2009.09.007
Zhang, Min ; Coen, John J. ; Suzuki, Yoshiyuki ; Siedow, Michael R. ; Niemierko, Andrzej ; Khor, Li Yan ; Pollack, Alan ; Zhang, Yifen ; Zietman, Anthony L. ; Shipley, William U. ; Chakravarti, Arnab. / Survivin is a potential mediator of prostate cancer metastasis. In: International Journal of Radiation Oncology Biology Physics. 2010 ; Vol. 78, No. 4. pp. 1095-1103.
@article{d7abc12473fd44d2b1d531644b13b813,
title = "Survivin is a potential mediator of prostate cancer metastasis",
abstract = "Purpose: We examined whether Survivin expression is associated with an increased risk of metastasis in prostate cancer. Methods and Materials: A total of 205 patients with T1 (23{\%}) and T2 (77{\%}) prostate cancer were treated with conventional external beam radiation therapy from 1991 to 1993 at the Massachusetts General Hospital. Of the patients, 62 had adequate and suitable-stained tumor material for Survivin analysis. Median follow-up was 102 months (range, 5-127 months). Distant failure was determined on the basis of clinical criteria. In preclinical studies, replication-deficient adenovirus encoding phosphorylation-defective Survivin Thr34→Ala dominant-negative mutant pAd-S(T34A) or short hairpin RNA (shRNA) was used to inhibit Survivin in prostate cancer models, and the cell motility, morphology, and metastasis were investigated. Results: Our correlative data on men with early-stage (T1/T2) prostate cancers treated at Massachusetts General Hospital by definitive radiotherapy indicated that overexpression of Survivin (positive staining in ≥10{\%} cells) was associated with a significantly increased risk for the subsequent development of distant metastasis (p = 0.016) in the univariate analysis. In the multivariate analysis, overexpression of Survivin remained an independent predictor of distant metastasis (p = 0.008). The inhibition of Survivin dramatically inhibited invasiveness of prostate cancer cells in the in vitro invasion assay and spontaneous metastasis in the Dunning prostate cancer in vivo model. Furthermore, attenuation of Survivin resulted in changes in the microtubule cytoskeleton, loss of cellular polarity, and loss of motility. Conclusions: This study suggests that Survivin may be a potentially important prognostic marker and promising therapeutic target in metastatic prostate cancer.",
keywords = "Metastasis, Prostate cancer, Survivin",
author = "Min Zhang and Coen, {John J.} and Yoshiyuki Suzuki and Siedow, {Michael R.} and Andrzej Niemierko and Khor, {Li Yan} and Alan Pollack and Yifen Zhang and Zietman, {Anthony L.} and Shipley, {William U.} and Arnab Chakravarti",
year = "2010",
month = "11",
day = "4",
doi = "10.1016/j.ijrobp.2009.09.007",
language = "English",
volume = "78",
pages = "1095--1103",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Survivin is a potential mediator of prostate cancer metastasis

AU - Zhang, Min

AU - Coen, John J.

AU - Suzuki, Yoshiyuki

AU - Siedow, Michael R.

AU - Niemierko, Andrzej

AU - Khor, Li Yan

AU - Pollack, Alan

AU - Zhang, Yifen

AU - Zietman, Anthony L.

AU - Shipley, William U.

AU - Chakravarti, Arnab

PY - 2010/11/4

Y1 - 2010/11/4

N2 - Purpose: We examined whether Survivin expression is associated with an increased risk of metastasis in prostate cancer. Methods and Materials: A total of 205 patients with T1 (23%) and T2 (77%) prostate cancer were treated with conventional external beam radiation therapy from 1991 to 1993 at the Massachusetts General Hospital. Of the patients, 62 had adequate and suitable-stained tumor material for Survivin analysis. Median follow-up was 102 months (range, 5-127 months). Distant failure was determined on the basis of clinical criteria. In preclinical studies, replication-deficient adenovirus encoding phosphorylation-defective Survivin Thr34→Ala dominant-negative mutant pAd-S(T34A) or short hairpin RNA (shRNA) was used to inhibit Survivin in prostate cancer models, and the cell motility, morphology, and metastasis were investigated. Results: Our correlative data on men with early-stage (T1/T2) prostate cancers treated at Massachusetts General Hospital by definitive radiotherapy indicated that overexpression of Survivin (positive staining in ≥10% cells) was associated with a significantly increased risk for the subsequent development of distant metastasis (p = 0.016) in the univariate analysis. In the multivariate analysis, overexpression of Survivin remained an independent predictor of distant metastasis (p = 0.008). The inhibition of Survivin dramatically inhibited invasiveness of prostate cancer cells in the in vitro invasion assay and spontaneous metastasis in the Dunning prostate cancer in vivo model. Furthermore, attenuation of Survivin resulted in changes in the microtubule cytoskeleton, loss of cellular polarity, and loss of motility. Conclusions: This study suggests that Survivin may be a potentially important prognostic marker and promising therapeutic target in metastatic prostate cancer.

AB - Purpose: We examined whether Survivin expression is associated with an increased risk of metastasis in prostate cancer. Methods and Materials: A total of 205 patients with T1 (23%) and T2 (77%) prostate cancer were treated with conventional external beam radiation therapy from 1991 to 1993 at the Massachusetts General Hospital. Of the patients, 62 had adequate and suitable-stained tumor material for Survivin analysis. Median follow-up was 102 months (range, 5-127 months). Distant failure was determined on the basis of clinical criteria. In preclinical studies, replication-deficient adenovirus encoding phosphorylation-defective Survivin Thr34→Ala dominant-negative mutant pAd-S(T34A) or short hairpin RNA (shRNA) was used to inhibit Survivin in prostate cancer models, and the cell motility, morphology, and metastasis were investigated. Results: Our correlative data on men with early-stage (T1/T2) prostate cancers treated at Massachusetts General Hospital by definitive radiotherapy indicated that overexpression of Survivin (positive staining in ≥10% cells) was associated with a significantly increased risk for the subsequent development of distant metastasis (p = 0.016) in the univariate analysis. In the multivariate analysis, overexpression of Survivin remained an independent predictor of distant metastasis (p = 0.008). The inhibition of Survivin dramatically inhibited invasiveness of prostate cancer cells in the in vitro invasion assay and spontaneous metastasis in the Dunning prostate cancer in vivo model. Furthermore, attenuation of Survivin resulted in changes in the microtubule cytoskeleton, loss of cellular polarity, and loss of motility. Conclusions: This study suggests that Survivin may be a potentially important prognostic marker and promising therapeutic target in metastatic prostate cancer.

KW - Metastasis

KW - Prostate cancer

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=77958465419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958465419&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2009.09.007

DO - 10.1016/j.ijrobp.2009.09.007

M3 - Article

C2 - 20231071

AN - SCOPUS:77958465419

VL - 78

SP - 1095

EP - 1103

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -